Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort-Reference-Cited by-同舟云学术

Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

Published:2022-12 Issue:12 Volume:4 Page:e862-e872
ISSN:2589-7500
Container-title:The Lancet Digital Health
language:en
Short-container-title:The Lancet Digital Health

Author:

Fainberg Hernan P,Oldham Justin M,Molyneaux Philip L,Allen Richard J,Kraven Luke M,Fahy William A,Porte Joanne,Braybrooke Rebecca,Saini Gauri,Karsdal Morten A,Leeming Diane J,Sand Jannie M B,Triguero Isaac,Oballa Eunice,Wells Athol U,Renzoni Elisabetta,Wain Louise V,Noth Imre,Maher Toby M,Stewart Iain D,Jenkins R Gisli

Publisher

Elsevier BV

Subject

Health Information Management,Decision Sciences (miscellaneous),Health Informatics,Medicine (miscellaneous)

Reference30 articles.

1. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline;Raghu;Am J Respir Crit Care Med,2015

2. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium;Nathan;Chest,2011

3. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis;Reichmann;BMC Pulm Med,2015

4. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis;Flaherty;Eur Respir J,2018

5. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis;Nathan;Thorax,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation;The Lancet Respiratory Medicine;2024-09

2. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis;American Journal of Respiratory and Critical Care Medicine;2024-08-15

3. Inter-reader reproducibility of a radiographic grading system for usual interstitial pneumonitis validates its use as a surrogate endpoint in clinical trials;Imaging;2024-06-26

4. Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis;Scandinavian Journal of Immunology;2024-06-07

5. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial;American Journal of Respiratory and Critical Care Medicine;2024-05-01